Bruker (NASDAQ:BRKR) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Bruker (NASDAQ:BRKR) issued its quarterly earnings data on Thursday. The medical research company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01, Zacks reports. Bruker had a net margin of 9.41% and a return on equity of 21.52%. Bruker updated its FY 2025 guidance to 2.670-2.720 EPS.

Bruker Price Performance

Shares of BRKR stock traded down $1.77 on Thursday, hitting $49.88. 1,396,737 shares of the stock traded hands, compared to its average volume of 1,550,197. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. Bruker has a 52 week low of $48.07 and a 52 week high of $94.86. The firm has a 50 day simple moving average of $57.88 and a two-hundred day simple moving average of $60.77. The firm has a market cap of $7.56 billion, a price-to-earnings ratio of 23.98, a PEG ratio of 3.81 and a beta of 1.16.

Analysts Set New Price Targets

BRKR has been the topic of several research analyst reports. Guggenheim reissued a “buy” rating on shares of Bruker in a report on Friday, January 17th. Citigroup lowered their target price on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. TD Cowen cut their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective on the stock in a research note on Thursday, December 5th. Finally, Bank of America boosted their target price on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Bruker currently has an average rating of “Moderate Buy” and a consensus price target of $74.09.

Insider Buying and Selling

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were acquired at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 28.30% of the stock is currently owned by insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.